It turns out that most Americans know very little about the state of their own medical benefits, particularly when it comes to out-of-pocket healthcare costs.
A survey released by Sun Life yesterday revealed that a whopping 54% of working Americans don’t know what the out-of-pocket maximum is for their own healthcare plans.
This statistic truly highlights the financial risk associated with individuals trying to save for retirement and successfully grow their wealth: that such planning cannot accurately be achieved without knowing first what kind of financial effect a major medical event could one day have on them.
Don’t Miss:Eight Times the Government Was Warned About Obamacare Fraud – and Did Nothing
To make matters worse, a particular niche of those surveyed revealed themselves to be arguably in an even tougher financial spot…
Top Medical Stocks To Watch For 2018: Nustar Energy L.P.(NS)
- [By Roberto Pedone]
One technology player that insiders are active in here is Jive Software (NS), which provides a social business software platform to businesses, government agencies, and other enterprises. Insiders are buying this stock into massive weakness, since shares are down sharply by 43% so far in 2014.
Jive Software has a market cap of $446 million and an enterprise value of $365 million. This stock trades at a fair valuation, with a price-to-sales of 2.68 and a price-to-book of 5.67. Its estimated growth rate for this year is 45.5%, and for next year it’s pegged at 30%. This is a cash-rich company, since the total cash position on its balance sheet is $98.18 million and its total debt is $6.60 million.
A director just bought 260,819 shares, or about $1.71 million worth of stock, at $6.53 to $6.60 per share.
From a technical perspective, JIVE is currently trending just above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently pulled back off its short-term high of $7.14 a share with heavy downside volume flows. That drop has now pushed the stock to right above its 50-day moving average at $6.10 a share.
If you’re bullish on JIVE, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.10 a share and then once it breaks out above some key near-term overhead resistance levels at $7.14 a share to its 200-day moving average of $7.43 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 557,678 shares. If that breakout triggers soon, then JIVE will set up to re-test or possibly take out its next major overhead resistance levels $8.50 to $9 a share, or even $9.50 to $10 a share.
Must Read: 10 Stocks George Soros Is Buying
Top Medical Stocks To Watch For 2018: Graco Inc.(GGG)
- [By Joel Elconin]
At this time, the only relevant news to the Gold market and Gold stocks was the halt of Graco Inc. (NYSE: GGG), which was down $0.80 at $84.64 and just reopened at $82.20.
- [By Lisa Levin]
In trading on Thursday, industrials shares fell by 0.83 percent. Meanwhile, top losers in the sector included Graco Inc. (NYSE: GGG), down 9 percent, and Southwest Airlines Co (NYSE: LUV), down 11 percent.
Top Medical Stocks To Watch For 2018: Ideal Power Inc.(IPWR)
- [By Logan Wallace]
Ideal Power (NASDAQ: IPWR) and Hollysys Automation Technologies (NASDAQ:HOLI) are both small-cap industrial products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.
- [By Jim Robertson]
On Thursday, our Under the Radar Moversnewslettersuggested smallcap electrical power conversion product stock Ideal Power Inc (NASDAQ: IPWR)as a long trade:
Top Medical Stocks To Watch For 2018: SPDR S&P Biotech ETF (XBI)
- [By ]
More importantly, the SPDR S&P Biotech ETF (NYSE:XBI) has proven resilient during the volatility spike and selloff.
In fact, XBI never closed significantly below its 50-day moving average as investors dumped stocks. That turned out to be a huge tell
- [By Money Morning News Team]
But the biotech sector crushed the market, with the SPDR S&P Biotech ETF (NYSE: XBI) returning a market-beating 43.36% in 2017, nearly double the broader S&P 500.
- [By WWW.KIPLINGER.COM]
Theres been follow-up, too: Valeant Pharmaceuticals Intl Inc (VRX) had to face the Senate in April for aggressively hiking prices on its drugs. Now Mylan NV (MYL) is answering to the government soon after a story showed that EpiPen prices have rocketed 400% since 2008 with no significant improvements to the treatment. This scandal, too, is rocking biotechs including (Link]recommendation SPDR S&P Biotech ETF (XBI).
- [By ]
The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.
- [By ]
Fast forward 12 months and the SPDR S&P Biotech ETF (NYSE:XBI) is higher by almost 50%. But this rally aint over yet. The beginning of 2018 trading is already flashing a new biotech breakout a move that could cement these stocks as some of the years most explosive market leaders.
Top Medical Stocks To Watch For 2018: Luxoft Holding, Inc.(LXFT)
- [By Steve Symington]
Luxoft Holding(NYSE:LXFT)announced strong fiscal fourth-quarter results on Monday, after the market closed. Similar to its modest post-earnings drop in February, shares of the software development specialist fell 3.6% on Tuesday as investors absorbed the news.